 safeti toler cyclosporin sandimmun idiopath nephrot syndrom collabor studi group sandimmun nephrot syndrom safeti toler cyclosporin cya sandimmun idiopath nephrot syndrom patient clinic studi major minimal-chang nephropathi mcn focal-segment glomerulosclerosi fsg safeti experi patient year cya exposur initi cya dose mg/kg/day adult mg/kg/day children efficaci advers reaction relev cya-induc renal dysfunct patient fsg abnorm baselin renal function renal toler patient complet remiss nephrot syndrom treatment latter risk low cya treatment month treatment sixty-nin patient renal biopsi year continu cya therapi cya-associ nephropathi interstiti fibrosi patient kidney biopsi advis mcn patient year cya therapi hypertens convent antihypertens therapi infecti complic cours unusu malign patient hodgkin lymphoma overal advers reaction cya treatment discontinu patient half renal dysfunct